

Date: 19.07.2023

To

BSE Limited 25th Floor Phiroze Jeebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051 NSE Code: MEDICAMEQ
---	--

Subject: Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that, MBL has successfully filed first ANDA in eCTD format for BORTEZOMIB FOR injection 3.5 MG/VIAL with USFDA (US Food and Drug Administration).

This is major milestone for the Company which will trigger USFDA Audit in due course of time.

We further wish to inform that the BORTEZOMIB API has been developed IN HOUSE by its R&D and the API is being manufactured by Shivalik Rasayan Ltd (Holding company of MBL) who has already filed DMF of BORTEZOMIB API with USFDA and have authorised Medicamen Biotech Limited to use the API for manufacture of BORTEZOMIB injection 3.5 MG/VIAL.

The same has been informed to USFDA.

Kindly take the same on your records and oblige.

Thanking You

Yours truly,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS44157